SCHEMBL26587204

SCHEMBL26587204

C=C(C)C(=O)N1CC2(CC=C(c3c(-c4ccc(Oc5ncccn5)cc4)c4c(N)ncnc4n3C)CC2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ FGFR1 P11362 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR4 P22455 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ BTK Q06187 19/20 0.40
▸ BLK P51451 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ RET P07949 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ TEC P42680 1/20 0.39
▸ TXK P42681 1/20 0.39
▸ BMX P51813 1/20 0.39
▸ ITK Q08881 1/20 0.39
▸ ERBB4 Q15303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26587174 0.90 BTK (0.47) BTKBLKEGFRERBB2RET
SCHEMBL30582573 0.88 SRC (0.40) BTKBLKEGFRERBB2RET
SCHEMBL26105368 0.88 SRC (0.40) BTKBLKEGFRERBB2RET
SCHEMBL30582498 0.88 BTK (0.50) BTKBLKEGFRERBB2RET
SCHEMBL26105312 0.85 SRC (0.40) BTKEGFRRET
SCHEMBL30582598 0.85 SRC (0.40) BTKEGFRRET
SCHEMBL22676001 0.85 CYP3A4 (0.43) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL26106963 0.85 BTK (0.37) CYP3A4CYP2D6FGFR1CYP2C9FGFR2
SCHEMBL26587296 0.85 BTK (0.47) FGFR1FGFR2FGFR4BTKBLK
SCHEMBL26106734 0.84 LCK (0.38) BTKBLKEGFRERBB2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP claimed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN claimed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO claimed
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP disclosed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback